Chemodenervation of the Larynx
AbstractBotulinum neurotoxin (BoNT) has existed for thousands of years; however, it was not medically utilized until investigations into its therapeutic use began in sincerity during the late 1970s and 1980s. This, coupled with the reclassification of spasmodic dysphonia as a focal dystonia, led to the use of chemodenervation for this disorder, which has since become a refined technique. Indeed, due to its safety and efficacy, BoNT has been investigated in multiple neurolaryngology disorders, including spasmodic dysphonia, vocal tremor, and muscle tension dysphonia. BoNT has been shown to be a useful and safe adjunct in the treatment for these disorders and may reduce or eliminate oral pharmacotherapy and/or prevent the need for a surgical intervention. We present the historical background, development, proposed mechanisms of action, uses, and techniques for administering BoNT for laryngeal disorders, with a particular focus on spasmodic dysphonia. View Full-Text
Share & Cite This Article
Kaye, R.; Blitzer, A. Chemodenervation of the Larynx. Toxins 2017, 9, 356.
Kaye R, Blitzer A. Chemodenervation of the Larynx. Toxins. 2017; 9(11):356.Chicago/Turabian Style
Kaye, Rachel; Blitzer, Andrew. 2017. "Chemodenervation of the Larynx." Toxins 9, no. 11: 356.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.